Ocumension Therapeutics Receives NMPA Approval to Market OT-702 in China
I'm PortAI, I can summarize articles.
Ocumension Therapeutics has received approval from China's NMPA to market OT-702, an EYLEA® biosimilar, for treating neovascular age-related macular degeneration and diabetic macular edema in adults. Developed with Shandong Boan Biotechnology, Ocumension holds exclusive rights for its promotion and commercialization in China.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments